IGOB131 As A GLP-1 Modulator For Metabolic Disorders In Adults With Obesity

Obesity is a complex, chronic disease characterized by excessive adiposity and associated with a markedly increased risk of Type 2 Diabetes, cardiovascular disease, and systemic inflammation. Its global prevalence continues to rise, imposing a substantial burden on healthcare systems and underscoring the urgent need for safe, effective, and accessible therapeutic strategies. While lifestyle modification remains the cornerstone of management, long-term adherence and sustained efficacy are often limited, prompting increasing interest in targeted metabolic interventions.

Among emerging therapeutic targets, the incretin system, particularly Glucagon-like peptide-1 (GLP-1), has gained considerable attention. GLP-1 is an intestinal hormone secreted by enteroendocrine L-cells in response to nutrient intake and plays a central role in glucose homeostasis and energy balance. It enhances glucose-dependent insulin secretion, suppresses glucagon release, delays gastric emptying, and promotes satiety. However, the biological activity of endogenous GLP-1 is short-lived due to rapid degradation by Dipeptidyl peptidase-4 (DPP-4), a widely expressed serine protease that cleaves incretin hormones, limiting their physiological effects.

Pharmacological targeting of the incretin axis has evolved rapidly in recent years, with GLP-1 receptor agonists emerging as transformative therapies for obesity and metabolic disease. Agents such as semaglutide and liraglutide have demonstrated clinically meaningful and sustained weight loss in both randomized trials and real-world settings, with semaglutide achieving greater reductions compared to liraglutide over one year in clinical practice. Furthermore, recent systematic reviews and meta-analyses confirm that GLP-1 receptor agonists produce significant reductions in body weight, glycemic indices, and cardiometabolic risk factors across diverse populations.

In parallel, DPP-4 inhibitors such as sitagliptin enhance endogenous incretin activity by preventing GLP-1 degradation, although their metabolic effects are generally more modest and weight-neutral. Despite the clinical success of incretin-based pharmacotherapies, their use may be limited by cost, accessibility, and tolerability, particularly in low- and middle-income settings. These limitations have intensified interest in alternative strategies capable of modulating the incretin system through physiological and potentially more accessible mechanisms.

Nutraceutical approaches represent a promising avenue in this context. Bioactive plant-derived compounds have been shown to influence metabolic pathways involved in appetite regulation, glucose metabolism, and inflammation. IGOB131, a standardized botanical extract derived from Irvingia gabonensis, has been developed for metabolic health, with prior clinical studies demonstrating improvements in body weight, lipid profile, and glycemic control. However, its potential role in modulating incretin physiology-particularly GLP-1 secretion and DPP-4 activity-remains insufficiently characterized.

Beyond metabolic dysregulation, obesity is increasingly recognized as a state of chronic low-grade inflammation driven by adipose tissue expansion and immune cell activation. Pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) contribute to insulin resistance and cardiometabolic risk. Notably, recent evidence indicates that GLP-1-based therapies exert pleiotropic effects beyond glycemic control, including anti-inflammatory actions and benefits across multiple organ systems. Additionally, emerging mechanistic and translational studies highlight the expanding role of GLP-1 signalling in immunometabolic regulation and multi-organ protection.

This study is designed to investigate the effects of IGOB131 on key components of metabolic regulation in adults with obesity. Specifically, the impact of IGOB131 on fasting and postprandial GLP-1 levels, DPP-4 activity, anthropometric indices, glycemic parameters, and inflammatory markers will be evaluated in a randomised, double-blind, placebo-controlled trial. The investigators hypothesise that IGOB131 may enhance GLP-1 bioavailability through dual mechanisms-stimulating endogenous secretion and reducing enzymatic degradation-thereby improving metabolic and inflammatory outcomes.